Document is current
Any future updates will be listed below
-
Authors
Martins, Ana Luiza Valle
Annoni, Filippo
da Silva, Filipe Alex
Bolais-Ramos, Lucas
de Oliveira, Gisele Capanema
Ribeiro, Renata Cunha
Diniz, Mirella Monique Lana
Silva, Thuanny Granato Fonseca
Pinheiro, Beatriz Dias
Rodrigues, Natália Abdo
dos Santos Matos, Alana Helen
Motta-Santos, Daisy
Campagnole-Santos, Maria José
Verano-Braga, Thiago
Taccone, Fabio Silvio
Santos, Robson Augusto Souza
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04633772 at ClinicalTrials.govDocuments that mention this clinical trial
Angiotensin-(1–7) infusion in COVID-19 patients admitted to the ICU: a seamless phase 1–2 randomized clinical trial
https://doi.org/10.1186/s13613-024-01369-0
-
Funding
Funding for this research was provided by:
Université Libre de Bruxelles (5C06G000010)
FAPEMIG (APQ-00325-20)
- License Information
-
More Information
Article History
Received: 30 March 2024
Accepted: 17 August 2024
First Online: 4 September 2024
Declarations
:
: The authors of the trial declared to have no conflict of interest. Prof Robson is the CEO of the company Angitec, which provided economic and logistic support without any monetary or contractual compensation.
